DYAI Dyadic International, Inc.

Dyadic is a global biotechnology company focused on further improving and leveraging the patented and proprietary C1 expression system to help bring biologic vaccines and drugs to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers to improve access and cost to patients and the healthcare system but most importantly to save lives. The company's stock was previously traded OTC but is now traded on an exchange.

As of 12/03/2021     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  11/05/2004
Outstanding shares:  28,079,157
Average volume:  190,702
Market cap:   $99,961,799
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    26745T101
ISIN:        US26745T1016
Valuation   (See tab for details)
PE ratio:   -8.80
PB ratio:   4.35
PS ratio:   41.03
Return on equity:   -49.39%
Net income %:   -443.95%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy